These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28438091)

  • 1. Analytic Response Curves of Clinical Breast Cancer IHC Tests.
    Vani K; Sompuram SR; Schaedle AK; Balasubramanian A; Bogen SA
    J Histochem Cytochem; 2017 May; 65(5):273-283. PubMed ID: 28438091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control.
    Vani K; Sompuram SR; Schaedle AK; Balasubramanian A; Pilichowska M; Naber S; Goldsmith JD; Chang KG; Noubary F; Bogen SA
    J Histochem Cytochem; 2017 Aug; 65(8):463-477. PubMed ID: 28665229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection.
    Sompuram SR; Vani K; Schaedle AK; Balasubramanian A; Bogen SA
    Arch Pathol Lab Med; 2018 Jul; 142(7):851-862. PubMed ID: 29595317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
    Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
    Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardizing Immunohistochemistry: A New Reference Control for Detecting Staining Problems.
    Sompuram SR; Vani K; Tracey B; Kamstock DA; Bogen SA
    J Histochem Cytochem; 2015 Sep; 63(9):681-90. PubMed ID: 25940339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
    Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
    Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
    Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
    Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
    Chu JS; Lee WJ; Chen KM; Hsu HC
    J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
    Mann GB; Fahey VD; Feleppa F; Buchanan MR
    J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Linear Range HER2/Estrogen Receptor/Progesterone Receptor IHControls for Daily Quality Assurance.
    Sompuram SR; Vani K; Ryan L; Johnson C; Szabolcs M; Peruyero L; Balaton A; Pierrot S; Joseph L; Pilichowska M; Naber S; Goldsmith J; Green S; Bogen SA
    Am J Clin Pathol; 2023 Mar; 159(3):274-282. PubMed ID: 36779320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
    Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
    Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells.
    Maleki S; Dorokhova O; Sunkara J; Schlesinger K; Suhrland M; Oktay MH
    Diagn Cytopathol; 2013 Oct; 41(10):864-70. PubMed ID: 23447357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
    Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metaplastic mammary carcinoma with discrepant hormone receptor results by IHC and RT-PCR.
    Elias AD; Sams S
    Oncology (Williston Park); 2013 Jun; 27(6):526-7, 566. PubMed ID: 23909065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.